107
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection

, , , , , , , , , , , & show all
Pages 1327-1338 | Published online: 07 May 2020

References

  • Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749–1761. doi:10.1016/S0140-6736(14)60121-524480518
  • Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2019;156:1368–1380. doi:10.1053/j.gastro.2018.12.00530552895
  • Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–1561. doi:10.1002/hep.2553222183941
  • Kang CI, Song JH, Chung DR, et al. Liver cirrhosis as a risk factor for mortality in a national cohort of patients with bacteremia. J Infect. 2011;63:336–343. doi:10.1016/j.jinf.2011.07.01221835195
  • National Guideline C. National Institute for Health and Care Excellence: Guidance Cirrhosis in Over 16s: Assessment and Management. National Institute for Health and Care Excellence (UK); 2016.
  • Leber B, Spindelboeck W, Stadlbauer V. Infectious complications of acute and chronic liver disease. Semin Respir Crit Care Med. 2012;33:80–95. doi:10.1055/s-0032-130173722447263
  • Bartoletti M, Giannella M, Lewis R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clin Microbiol Infect. 2018;24:546.e1–546.e8. doi:10.1016/j.cmi.2017.08.001
  • Bartoletti M, Giannella M, Caraceni P, et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J Hepatol. 2014;61:51–58. doi:10.1016/j.jhep.2014.03.02124681345
  • Bartoletti M, Giannella M, Lewis RE, Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016;7:309–319. doi:10.1080/21505594.2016.114116226864729
  • Linderoth G, Jepsen P, Schonheyder HC, Johnsen SP, Sorensen HT. Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: a population-based cohort study. Alcohol Clin Exp Res. 2006;30:636–641. doi:10.1111/j.1530-0277.2006.00074.x16573581
  • Fernandez J, Acevedo J. New antibiotic strategies in patients with cirrhosis and bacterial infection. Expert Rev Gastroenterol Hepatol. 2015;9:1495–1500. doi:10.1586/17474124.2015.110007526465070
  • Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310–1324. doi:10.1016/j.jhep.2014.01.02424530646
  • Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Supp 1):S1–S12. doi:10.1016/S0168-8278(12)60002-622300459
  • Mucke MM, Mayer A, Kessel J, et al. Quinolone- and multidrug-resistance predict failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. Clin Infect Dis. 2019. doi:10.1093/cid/ciz540
  • Stewardson AJ, Marimuthu K, Sengupta S, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019;19:601–610. doi:10.1016/S1473-3099(18)30792-831047852
  • Hayden MK, Won SY. Carbapenem-sparing therapy for extended-spectrum beta-Lactamase-producing E coli and Klebsiella pneumoniae Bloodstream Infection: the search continues. JAMA. 2018;320:979–981. doi:10.1001/jama.2018.1256530208439
  • Ko JH, Lee NR, Joo EJ, et al. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study. Eur J Clin Microbiol Infect Dis. 2018;37:305–311. doi:10.1007/s10096-017-3133-229177611
  • Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167–174. doi:10.1093/cid/cir79022057701
  • Perez F, Bonomo RA. Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β-lactamase-producing bacteria? Clin Infect Dis. 2012;54:175–177. doi:10.1093/cid/cir79322057699
  • Su J, Guo Q, Li Y, et al. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73:3176–3180. doi:10.1093/jac/dky32330099554
  • Bin C, Hui W, Renyuan Z, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis. 2006;56:351–357. doi:10.1016/j.diagmicrobio.2006.06.01516934430
  • Kilgore M, Brossette S. Cost of bloodstream infections. Am J Infect Control. 2008;36:S172.e1–S172.e3. doi:10.1016/j.ajic.2008.10.004
  • Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med. 1999;3:976–981. doi:10.1164/ajrccm.160.3.9808145
  • Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140:26–32. doi:10.7326/0003-4819-140-1-200401060-0000814706969
  • Lee CC, Wang JL, Lee CH, et al. Clinical benefit of appropriate em*pirical fluoroquinolone therapy for adults with community-onset bacteremia in comparison with third-generation-cephalosporin therapy. Antimicrob Agents Chemother. 2017;61:e02174–16. doi:10.1128/AAC.02174-1627855072
  • Liang X, Fan Y, Yang M, et al. A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring. Clin Infect Dis. 2018;67:S249–S255. doi:10.1093/cid/ciy68030423040
  • Xie Y, Tu B, Xu Z, et al. Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis. Sci Rep. 2017;7:11482. doi:10.1038/s41598-017-11587-128904387
  • Novovic S, Semb S, Olsen H, Moser C, Knudsen JD, Homann C. First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage. Scand J Gastroenterol. 2012;47:212–216. doi:10.3109/00365521.2011.64550222191479
  • Nelson AN, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection. 2017;45:613–620. doi:10.1007/s15010-017-1020-528478600
  • Yang Q, Zhang H, Cheng J, et al. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum beta-lactamases in China. Int J Antimicrob Agents. 2015;45:485–490. doi:10.1016/j.ijantimicag.2014.11.01225600890
  • Loo AS, Gerzenshtein L, Ison MG. Antimicrobial drug-induced thrombocytopenia: a review of the literature. Semin Thromb Hemost. 2012;38:818–829. doi:10.1055/s-0032-132888223081819
  • Li Y, Hu YF, Peng FC. Evidence-based analysis of thrombocytopenia caused by cefoperazone/sulbactam. Chin J Hosp Pharm. 2009;44:1938–1941.